Sam Waksal
Founder/CEO
Graviton Bioscience
Graviton Bioscience Corp is developing therapeutics targeting Rho-associated protein kinase (ROCK2) to treat autoimmune, cancer, and fibrotic diseases. Their platform focuses on engineering drug candidates that address the underlying cellular contractility and fibrosis associated with these serious conditions.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$93.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Autoimmune, cancer, and fibrotic diseases share underlying mechanisms of cellular contractility and fibrosis, which contribute to disease progression and limited treatment options. Current therapies often fail to address these core mechanisms, resulting in incomplete responses and disease recurrence.
Solution
Graviton Bioscience Corp is developing therapeutics that target Rho-associated protein kinase 2 (ROCK2) to address the underlying cellular contractility and fibrosis associated with autoimmune, cancer, and fibrotic diseases. Their platform focuses on engineering drug candidates designed to modulate ROCK2 activity, thereby disrupting the signaling pathways that drive these pathological processes. By targeting ROCK2, Graviton aims to develop therapies that can effectively reduce cellular contractility, inhibit fibrosis, and ultimately improve outcomes for patients suffering from these serious conditions.
Target Audience
The primary target audience includes patients suffering from autoimmune, cancer, and fibrotic diseases, as well as the healthcare providers who treat them.
Features
- Development of therapeutics targeting Rho-associated protein kinase 2 (ROCK2)
- Focus on addressing cellular contractility and fibrosis
- Engineering of drug candidates to modulate ROCK2 activity